BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nagai T, Naiki T, Isobe T, Sugiyama Y, Etani T, Iida K, Nozaki S, Noda Y, Shimizu N, Tasaki Y, Mimura Y, Banno R, Kubota H, Hamamoto S, Kawai N, Yasui T. Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma. In Vivo 2021;35:2793-800. [PMID: 34410970 DOI: 10.21873/invivo.12565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Shindo T, Maehana T, Tanaka T, Hashimoto K, Kobayashi K, Takahashi A, Hotta H, Kunishima Y, Taguchi K, Tachiki H, Ito N, Matsukawa M, Kato R, Miyamoto S, Hinotsu S, Masumori N. Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study. Int J Urol 2022. [PMID: 35654444 DOI: 10.1111/iju.14941] [Reference Citation Analysis]